Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia.

BACKGROUND Non-adherence with recommended follow-up visits is a major barrier for completing treatment of viral hepatitis and is consequently associated with unfavorable outcomes of health services. OBJECTIVES To estimate the magnitude and identify perceived reasons and patient characteristics associated with loss to follow-up in a tertiary care setting. METHODS A two-step cross-sectional study design was used, including a chart review (2011) followed by phone survey (2012). Loss to follow-up was recorded among those who were diagnosed with hepatitis B (HBV) or C (HCV) during 2009-2010 but never returned for recommended/scheduled follow-up appointment(s). RESULTS A total of 328 patients (202 HBV and 126 HCV) were included in the current analysis. The average age was 49.6±17.9years, and 57% were males. Out of 328, 131 (40%) were not advised to do follow-up, and 98 (30%) were not doing follow-up. Perceived reasons for loss to follow-up were as follows: unaware that a follow-up appointment was scheduled (69%), never informed of need for follow-up by healthcare provider (15%), personal belief that follow-up was not necessary (9%), logistical reasons (3%) and other reasons (5%). Loss to follow-up was higher among those who had been diagnosed with HBV, referred by non-liver-related specialty, never advised to follow-up, unaware of their diagnosis, incorrectly identified their type of hepatitis, lacking hepatitis complications, having full medical coverage, pregnant, and those with low knowledge or negative attitude towards hepatitis. CONCLUSIONS Loss to follow-up is a significant problem among patients with hepatitis in a tertiary care center, with several patient and system failures being implicated.

[1]  R. D. de Man,et al.  Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. , 2004, Journal of hepatology.

[2]  L. Cheever,et al.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  P. Boyle,et al.  Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? , 2012, Social science & medicine.

[4]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[5]  O. Siddique,et al.  Hepatitis patients lost to follow-up at a liver centre in a tertiary care hospital of Karachi, Pakistan--a cross-sectional descriptive study. , 2013, JPMA. The Journal of the Pakistan Medical Association.

[6]  Z. Memish,et al.  Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  J. Heathcote,et al.  Sociocultural factors that potentially affect the institution of prevention and treatment strategies for hepatitis B in Chinese Canadians , 2009 .

[8]  N. Tan,et al.  What barriers do primary care physicians face in the management of patients with chronic hepatitis B infection in primary care? , 2005, Singapore medical journal.

[9]  A. Aljarbou The Emergent Concern of Hepatitis B globally with special attention to Kingdom of Saudi Arabia. , 2013, International journal of health sciences.

[10]  S. Shafran,et al.  Improving access to care by allowing self-referral to a hepatitis C clinic. , 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[11]  Joan M. Block,et al.  Is chronic hepatitis B being undertreated in the United States? , 2011, Journal of viral hepatitis.

[12]  R. Grant,et al.  Barriers to the treatment of hepatitis C , 2005 .

[13]  I. Kagevi,et al.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4 , 2009, Annals of Saudi medicine.

[14]  F. Sanai,et al.  Epidemiology of Viral Hepatitis in Saudi Arabia: Are We Off the Hook? , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[15]  V. Navarro,et al.  Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. , 2007, World journal of gastroenterology.

[16]  H. Toyoda,et al.  Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan , 2011, BMC Research Notes.

[17]  A. Butt,et al.  Reasons for non‐treatment of hepatitis C in veterans in care , 2005, Journal of viral hepatitis.

[18]  S. Smith,et al.  Barriers to accessing care in patients with chronic hepatitis C: the impact of depression , 2010, Alimentary pharmacology & therapeutics.

[19]  C. Mcgowan,et al.  Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[20]  W. Kim,et al.  Report on a single‐topic conference on “Chronic Viral Hepatitis–Strategies to Improve Effectiveness of Screening and Treatment” , 2012, Hepatology.

[21]  Z. Memish,et al.  Hepatitis B virus among Saudi National Guard personnel: seroprevalence and risk of exposure. , 2013, Journal of infection and public health.